Phase 2 N=24 Varenicline and Smoking Cessation in Schizophrenia
Schizophrenia · Smoking Cessation
Primary: Smoking Abstinence - Serum/Urine Measurements — 198.67; 207; 213.8; 22.57 ng/mL — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 D-serine for the Schizophrenia Prodrome
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms (SOPS) Negative Scale — 7.6; 11.3 SOPS negative final score — p=0.03
Phase 4 N=14 Varenicline Effects In Schizophrenic Smokers
Schizophrenia · Tobacco Use Disorder · Nicotine Dependance
Primary: Self Report of Smoking — 36.45; 17.25; 12.52 Cigarettes
N/A N=8 Clinical Interviews With Detainees With Early Psychosis
First-Episode Psychosis
Primary: Number of Referrals to Correctional Health Services (CHS) — 8 Participants
N/A N=191 Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis
Schizophrenia · First Episode Psychosis
Primary: Reducing the Duration of Untreated Psychosis — 5.32; 5.38 Days
N/A N=31 The Relationship Between Autobiographical Memory and Motivation
Psychosis
Primary: Post-Intervention Motivation Score — 81.01; 72.89 units on a scale
Early Phase 1 N=18 Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
Psychotic Disorders
Primary: Brief Psychiatric Rating Scale (Overall & Gorham, 1962) — -8.0; -11.6 percentage of total possible change
N/A N=60 mHealth for Psychosis Help-seeking
Psychosis
Primary: Change in Treatment Seeking Steps — 6.43; 10.08; 7.65; 9.58 score on a scale
Phase 2 N=77 Treatment of Psychosis and Agitation in Alzheimer's Disease
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
Phase 4 N=60 Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
Post-Schizophrenic Depression
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 8.31; 8.62 score on a scale
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs
N/A N=21 Families With Substance Use and Psychosis: A Pilot Study
Psychosis · Substance Use · Substance Use Disorders
Primary: Percentage of Sessions Completed — 100 percentage of intervention sessions
N/A N=65 Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
Psychosis · Substance Use · Substance Use Disorders
Primary: Family Wellbeing: Depression — 14.19; 10.82; 9.76; 11.67 score on a scale — p=0.026
N/A N=6 Feasibility Electrical Stimulation Study for Visual Hallucinations
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Steady State Visual Evoked Potential (ssVEP) — 1.725; 1.160; 1.180; 1.005 microvolts — p=0.10
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50